Sign In
Buy ELVN
$36.03
+0.510 (+1.44%)
At Close: Jun 03, 2026
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
04:52am, Saturday, 24'th Jan 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) insider Joseph Lyssikatos sold 20,000 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average p
Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
04:04am, Thursday, 15'th Jan 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) COO Anish Patel sold 48,300 shares of the firm's stock in a transaction that occurred on Friday, January 9th. The shares were sold at an ave
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars
02:16pm, Thursday, 08'th Jan 2026
Enliven Therapeutics Inc. (NASDAQ: ELVN) stock is trading higher on Thursday, with a session volume of 6.61 million compared to the average volume of 631.52 thousand as per data from Benzinga Pro.
Stocks Mixed as Defense Sector Charges Higher
12:15pm, Thursday, 08'th Jan 2026
Stocks are mixed as defense stocks surge, with the Dow Jones Industrial Average (DJI) up triple digits, while the Nasdaq Composite (IXIC) slides alongside tech
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
09:00am, Thursday, 08'th Jan 2026
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts ELVN-001 continues to demonstrate a favorable s
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
09:00am, Wednesday, 07'th Jan 2026
Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors Building on positive data reported in 202
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages
03:28am, Friday, 02'nd Jan 2026
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBe
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
04:21pm, Thursday, 11'th Dec 2025
BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small mole
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
09:00am, Thursday, 11'th Dec 2025
Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer Co-Founder Sam Kintz will assume a new position as Hea
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade
10:55am, Wednesday, 03'rd Dec 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 101.3% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is ques
Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy
07:55am, Tuesday, 18'th Nov 2025
Enliven Therapeutics remains overvalued relative to its early-stage pipeline progress and current financials. ELVN-001 shows promising safety and efficacy signals in heavily pretreated CML patients, w
Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect?
10:56am, Monday, 17'th Nov 2025
The mean of analysts' price targets for Enliven Therapeutics, Inc. (ELVN) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agre
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.20 Average Price Target from Brokerages
01:39am, Sunday, 16'th Nov 2025
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have been given an average rating of "Moderate Buy" by the six research firms that are covering the stock, MarketBeat Ratings repo
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
04:05pm, Wednesday, 12'th Nov 2025
Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 in 2026 Strong balance sheet with
Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know
10:56am, Friday, 12'th Sep 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 106.5% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is ques
